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Autophagy and endoplasmic reticulum (ER) stress are involved in the development, progression, and
chemoresistance of melanoma. We recently reported that oncogenic serine/threonine-protein kinase BRAF induces
chronic ER stress, hence increasing baseline autophagy and promoting chemoresistance. The attenuation of ER stress
restores basal autophagic activity and resensitizes melanoma cells to apoptosis.
Proliferation and cell death are finely
regulated and evolutionarily conserved
physiologic processes that work in contra-
position to play a pivotal role in the
homeostasis of a multicellular organism.
Indeed, in every organism several million
cells are thought to die every second and
this phenomenon of cellular demise is bal-
anced by cell proliferation. This epic bat-
tle represents a fundamental process
throughout the lifespan of an organism,
since an unbalanced equilibrium between
cell proliferation and death may result in
tumor development.
Importantly, most tumors are charac-
terized by an acquired desensitization to
apoptotic stimuli, mainly due to dysfunc-
tional apoptosis or deregulated prolifera-
tion, as a result of mutations, ablations, or
dysfunction of key genes of the 2 signaling
pathways.
Moreover, dysfunction or improper
activation or inhibition of other molecular
pathways may contribute to both tumor
growth and unresponsiveness of cancer
cells to therapy. Recent studies point to
dysregulation of the unfolded protein
response (UPR) and autophagy during
tumor development/progression and/or
under chemotherapeutic treatment that is
associated with poor clinical outcome.
Indeed, improper activity of these path-
ways negatively affects drug-induced
apoptosis.1,2
Both endoplasmic reticulum (ER)
stress and autophagy are primarily prosur-
vival pathways that are activated under
stress conditions such as nutrient shortage
and hypoxia, a typical feature of the solid
tumor microenvironment, and under che-
motherapy to actively counteract proapop-
totic stimuli. Thus, although targeting ER
stress and/or autophagy may provide a
considerable benefit for cancer therapy,
such potential is complicated by the inter-
connection of the 2 processes since each
can regulate the other. Moreover, in this
context the specific function of both ER
stress and autophagy is strictly dependent
on both tumor type and disease stage, as
demonstrated in melanoma.3
Cutaneous metastatic melanoma is one
of the most aggressive and difficult to treat
forms of human malignancy, and more-
over has an increasing incidence. Although
mutation of the serine/threonine-protein
kinase B-raf (BRAF), resulting in
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constitutive kinase activation, represents
the most characteristic feature of this
tumor (present in 70% of all melanomas),
other mutations are also involved. More-
over, many reports indicate that dysregu-
lation of autophagy and ER stress may
represent 2 key signaling pathways
involved in melanoma development,
progression, and resistance to therapy,
although an univocal interpretation is still
far from evident.4,5 Moreover, the under-
lying genotype of an individual melanoma
also appears to influence UPR and auto-
phagic functions, with BRAF in particular
appearing to have a direct effect on both
pathways.6,7 Indeed, oncogenic BRAF
reduces cell susceptibility to
ER stress-induced apoptosis
and concomitantly results in
higher basal autophagic
rates compared to BRAF
wild type melanoma cells,
although the underlying
molecular mechanisms
mediating this effect remain
unclear.6,7 Recently, we and
2 other research groups
independently identified 3
molecular pathways linking
oncogenic BRAF activity
and UPR induction in mela-
noma cells; these pathways
involve (i) eukaryotic trans-
lation initiation factor 4E
(eIF4E),8 (ii) mitogen-acti-
vated protein kinase 14
(MAPK14, also known as
p38)9 or (iii) glucose-regu-
lated protein 78kDa
(GRP78)10. Inhibition of
eIF4E phosphorylation as a
result of oncogenic BRAF-
dependent mitogen-acti-
vated protein kinase kinase/
extracellular signal-regulated
kinase (MEK/ERK) activa-
tion results in protein
hyperproduction and conse-
quent UPR induction.8
Oncogenic BRAF also
results in constitutive p38
activation, contributing to
ER stress sensor activation
and UPR tuning.9 Finally,
mutated BRAF may also
directly interact with
GRP78, thus relieving its
inhibitory activity on acti-
vating transcription factor 6
(ATF6), inositol-requiring
enzyme 1 (IRE1), and dou-
ble-stranded RNA activated
protein kinase (PKR)-like
endoplasmic reticulum
kinase (PERK) and stimulating the UPR
signaling pathway10 (Fig. 1).
ER stress activation per se enhances
tumor growth and inhibits cell death
induction,1 thus promoting tumor pro-
gression and chemoresistance. Moreover,
oncogenic BRAF-induced UPR also
results in autophagy enhancement in
Figure 1. ER stress induced by oncogenic BRAF and modulation of basal autophagy in melanoma. Oncogenic ser-
ine/threonine-protein kinase B-raf carrying the V>E mutation (BRAFV600E) stimulates endoplasmic reticulum (ER)
stress through the involvement of at least 3 major factors, glucose-regulated protein 78kDa (GRP78), eukaryotic
translation initiation factor 4E (eIF4E), and mitogen-activated protein kinase 14 (p38). Through direct interaction
with GRP78, mutant BRAF relieves its inhibitory activity toward the 3 stress sensors, activating transcription factor 6
(ATF6), inositol-requiring enzyme (IRE1), and double-stranded RNA activated protein kinase (PKR)-like endoplasmic
reticulum kinase (PERK),10 and thus inducing the unfolded protein response (UPR). Stimulation of the activity of the
mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling pathway drives
phosphorylation of the translational factor eIF4E, hyperstimulating the translational signaling pathway and resulting
in protein accumulation in the ER compartment;8 activation of p38 (through protein phosphorylation) drives the
activation of the above mentioned ER stress sensors, resulting in UPR.9 ER stress in turn enhances the activity of the
autophagic process through the PERK/activating transcription factor 4 (ATF4)/mammalian homolog of Drosophila
tribbles (TRB3) and the IRE1/TNF receptor-associated factor 2 (TRAF2)/apoptosis signal-regulating kinase 1 (ASK1)/c-
Jun N-terminal kinase (JNK) axes. In the first signaling pathway (B), active PERK phosphorylates the eukaryotic trans-
lation initiation factor 2a (eIF2a), a factor controlling the initiation of cap-dependent protein translation, thus stimu-
lating the IRES-dependent translational process. This favors accumulation of the transcription factor ATF4 that in
turn stimulates the synthesis of TRB3, which induces the autophagic process through inhibition of mammalian tar-
get of rapamycin (mTOR) activity. In parallel (A), active IRE1 recruits and activates the cytosolic kinase ASK1 through
the adapter molecule TRAF2, which in turn activates JNK. The latter phosphorylates the BECLIN 1 (BECN1) inhibitory
partners B-cell lymphoma 2 (BCL-2) and BCL2-like 1 isoform 1 (BCL-XL), resulting in BECN1 release and subsequent
autophagy induction. Therefore, mutant BRAF-mediated dysregulation of prosurvival pathways such as ER stress
and autophagy sustains tumor development and progression, and desensitizes cancer cells to therapy-induced apo-
ptosis (CHEMOs).
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melanoma cells, contributing to desensiti-
zation of cells to apoptosis induction.9,10
Importantly, we have revealed the under-
lying molecular mechanisms linking the 2
pathways in BRAF mutant melanoma
cells based on activation of (i) the PERK/
activating transcription factor 4 (ATF4)
axis of UPR, resulting in upregulation of
mammalian homolog of Drosophila trib-
bles (TRB3) and subsequent inhibition of
mammalian target of rapamycin (mTOR)
and consequent autophagy induction; ii)
the IRE1/TNF receptor-associated factor
2/apoptosis signal-regulating kinase 1/c-
Jun N-terminal kinase (IRE1/TRAF2/
ASK1/JNK) axis, thus resulting in phos-
phorylation of B-cell lymphoma 2 (BCL-
2)/BCL2-like 1 isoform 1 (BCL-XL),
BECLIN 1 (BECN1) release, and autoph-
agy induction9 (Fig. 1).
Inhibition of BRAF-mediated UPR
using the chemical chaperone 4-phenylbu-
tyric acid (4PBA) clearly resulted in basal
autophagy inhibition and, crucially, resen-
sitization to chemotherapy-stimulated
melanoma cell death.9
Collectively, these data indicate that,
although autophagy dysregulation
undoubtedly has a major impact in mela-
noma, oncogenic BRAF-stimulated UPR
assumes a pivotal role in melanoma tumor
progression and acquired chemoresistance
and, furthermore, directly controls the
autophagic process.
In conclusion, targeted therapies that
attenuate ER stress may represent a novel
and effective therapeutic strategy for mela-
noma with oncogenic BRAF.
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